Pfizer and its partner BioNTech are expected to ask the FDA to authorize a coronavirus vaccine for children 6 months to 4 years old, as a two-dose regimen, while the companies continue to research how well a three dose regimen works.
As the Omicron variant has swarmed the country, there has been a sharp increase in pediatric cases of the virus, according to the American Academy of Pediatrics, which gathers state-level data.